The State of the Union in Cancer Innovation
PM360
JULY 13, 2023
We are currently evaluating our lead OEC, OTX-2002, in our Phase 1/2 MYCHELANGELO I clinical program in patients with advanced hepatocellular carcinoma and other MYC-associated solid tumors. Preliminary data are expected in 2023. What Other Developments Within Oncology Excite You?
98 
Let's personalize your content